1932

Abstract

The immune system has evolved to respond not only to pathogens, but also to signals released from dying cells. Cell death through necrosis induces inflammation, whereas apoptotic cell death provides an important signal for tolerance induction. High mobility group box 1 (HMGB1) is a DNA-binding nuclear protein, released actively following cytokine stimulation as well as passively during cell death; it is the prototypic damage-associated molecular pattern (DAMP) molecule and has been implicated in several inflammatory disorders. HMGB1 can associate with other molecules, including TLR ligands and cytokines, and activates cells through the differential engagement of multiple surface receptors including TLR2, TLR4, and RAGE. RAGE is a multiligand receptor that binds structurally diverse molecules, including not only HMGB1, but also S100 family members and amyloid-β. RAGE activation has been implicated in sterile inflammation as well as in cancer, diabetes, and Alzheimer's disease. While HMGB1 through interactions with TLRs may also be important, this review focuses on the role of the HMGB1-RAGE axis in inflammation and cancer.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.immunol.021908.132603
2009-04-23
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/immunol/28/1/annurev.immunol.021908.132603.html?itemId=/content/journals/10.1146/annurev.immunol.021908.132603&mimeType=html&fmt=ahah

Literature Cited

  1. Foell D, Wittkowski H, Roth J. 1.  2007. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 3:382–90 [Google Scholar]
  2. Rubartelli A, Lotze MT. 2.  2007. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28:429–36 [Google Scholar]
  3. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. 3.  2004. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 279:17079–84 [Google Scholar]
  4. Foell D, Wittkowski H, Vogl T, Roth J. 4.  2007. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81:28–37 [Google Scholar]
  5. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG. 5.  et al. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9:857–65Demonstration that amyloid-β induces IL-1β secretion, dependent on NALP3. [Google Scholar]
  6. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 6.  2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–41 [Google Scholar]
  7. Martinon F, Mayor A, Tschopp J. 7.  2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229–65 [Google Scholar]
  8. Cayrol C, Girard JP. 8.  2009. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106:9021–26 [Google Scholar]
  9. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. 9.  2009. Interleukin-33—cytokine of dual function or novel alarmin?. Trends Immunol. 30:227–33 [Google Scholar]
  10. Gasse P, Riteau N, Charron S, Girre S, Fick L. 10.  et al. 2009. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 179:903–13 [Google Scholar]
  11. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H. 11.  et al. 2007. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J. Biol. Chem. 282:18265–75 [Google Scholar]
  12. Yan SF, Ramasamy R, Schmidt AM. 12.  2008. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 4:285–93 [Google Scholar]
  13. Yan SF, Ramasamy R, Schmidt AM. 13.  2009. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 11:e9 [Google Scholar]
  14. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. 14.  2007. RAGE: a potential target for Aβ-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 7:735–42 [Google Scholar]
  15. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. 15.  1993. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 21:3427–36 [Google Scholar]
  16. Thomas JO. 16.  2001. HMG1 and 2: architectural DNA-binding proteins. Biochem. Soc. Trans. 29:395–401 [Google Scholar]
  17. Thomas JO, Travers AA. 17.  2001. HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem. Sci. 26:167–74 [Google Scholar]
  18. Stros M, Stokrova J, Thomas JO. 18.  1994. DNA looping by the HMG-box domains of HMG1 and modulation of DNA binding by the acidic C-terminal domain. Nucleic Acids Res. 22:1044–51 [Google Scholar]
  19. Watson M, Stott K, Thomas JO. 19.  2007. Mapping intramolecular interactions between domains in HMGB1 using a tail-truncation approach. J. Mol. Biol. 374:1286–97 [Google Scholar]
  20. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N. 20.  et al. 2009. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7:17 [Google Scholar]
  21. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M. 21.  et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–51HMGB1 is released following cytokine stimulation and is important in sepsis. [Google Scholar]
  22. Scaffidi P, Misteli T, Bianchi ME. 22.  2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–95First report describing that for necrotic cell death to induce inflammation HMGB1 is required. [Google Scholar]
  23. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS. 23.  2006. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 291:C1318–25 [Google Scholar]
  24. Jiang W, Bell CW, Pisetsky DS. 24.  2007. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J. Immunol. 178:6495–503 [Google Scholar]
  25. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. 25.  2008. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21–32Demonstration that oxidation of HMGB1 is important in tolerance induction mediated by apoptotic cells. [Google Scholar]
  26. Ito I, Fukazawa J, Yoshida M. 26.  2007. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282:16336–44 [Google Scholar]
  27. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A. 27.  et al. 2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551–60 [Google Scholar]
  28. Youn JH, Shin JS. 28.  2006. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177:7889–97 [Google Scholar]
  29. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR. 29.  et al. 2002. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3:995–1001 [Google Scholar]
  30. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H. 30.  et al. 2003. IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170:3890–97 [Google Scholar]
  31. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D. 31.  et al. 2002. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99:12351–56 [Google Scholar]
  32. Wang H, Liao H, Ochani M, Justiniani M, Lin X. 32.  et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:1216–21 [Google Scholar]
  33. Ulloa L, Messmer D. 33.  2006. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 17:189–201 [Google Scholar]
  34. Kim JH, Kim SJ, Lee IS, Lee MS, Uematsu S. 34.  et al. 2009. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-β signaling pathway. J. Immunol. 182:2458–66 [Google Scholar]
  35. Andersson U, Erlandsson-Harris H. 35.  2004. HMGB1 is a potent trigger of arthritis. J. Intern. Med. 255:344–50 [Google Scholar]
  36. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. 36.  2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 81:49–58 [Google Scholar]
  37. Tian J, Avalos AM, Mao SY, Chen B, Senthil K. 37.  et al. 2007. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487–96HMGB1 is a component of DNA immune complexes and signals though TLR9 and RAGE. [Google Scholar]
  38. Sha Y, Zmijewski J, Xu Z, Abraham E. 38.  2008. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180:2531–37 [Google Scholar]
  39. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J. 39.  et al. 2007. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970–81 [Google Scholar]
  40. Messmer D, Yang H, Telusma G, Knoll F, Li J. 40.  et al. 2004. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173:307–13 [Google Scholar]
  41. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M. 41.  et al. 2005. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174:7506–15 [Google Scholar]
  42. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. 42.  2005. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35:2184–90 [Google Scholar]
  43. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M. 43.  et al. 2005. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174:7506–15 [Google Scholar]
  44. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. 44.  2007. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81:59–66 [Google Scholar]
  45. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T. 45.  et al. 2008. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180:2270–75 [Google Scholar]
  46. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. 46.  2000. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb. Haemost. 84:1087–94 [Google Scholar]
  47. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A. 47.  et al. 2007. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26:1129–39 [Google Scholar]
  48. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E. 48.  et al. 2003. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652–60 [Google Scholar]
  49. Liu JH, Li ZJ, Tang J, Liu YW, Zhao L. 49.  et al. 2006. High mobility group box-1 protein activates endothelial cells to produce cytokines and has synergistic effect with lipopolysaccharide in inducing interleukin-6 release. Zhonghua Yi Xue Za Zhi 86:1191–95 [Google Scholar]
  50. Agresti A, Bianchi ME. 50.  2003. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 13:170–78 [Google Scholar]
  51. Paull TT, Haykinson MJ, Johnson RC. 51.  1993. The nonspecific DNA-binding and -bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures. Genes Dev. 7:1521–34 [Google Scholar]
  52. Grosschedl R, Giese K, Pagel J. 52.  1994. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10:94–100 [Google Scholar]
  53. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. 53.  2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115:407–17 [Google Scholar]
  54. 54.  Deleted in proof. [Google Scholar]
  55. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. 55.  2004. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50:1861–72 [Google Scholar]
  56. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. 56.  2003. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171:3296–302 [Google Scholar]
  57. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U. 57.  et al. 2002. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46:191–201 [Google Scholar]
  58. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P. 58.  et al. 2008. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205:3007–18HMGB1-associated nucleosomes signal though TLR2 and induce cytokine secretion. [Google Scholar]
  59. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. 59.  2008. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. J. Immunol. 180:5067–74 [Google Scholar]
  60. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. 60.  2007. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol. Lett. 111:36–44 [Google Scholar]
  61. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. 61.  2009. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86:609–15 [Google Scholar]
  62. Chen GY, Tang J, Zheng P, Liu Y. 62.  2009. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323:1722–25Demonstrated a novel role for CD24-HMGB1 in distinguishing between microbial- and injury-associated inflammation during sterile inflammation. [Google Scholar]
  63. Van de Wouwer M, Collen D, Conway EM. 63.  2004. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler. Thromb. Vasc. Biol. 24:1374–83 [Google Scholar]
  64. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y. 64.  et al. 2005. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115:1267–74 [Google Scholar]
  65. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T. 65.  et al. 2007. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J. Thromb. Haemost. 5:109–16 [Google Scholar]
  66. Angus DC, Wax RS. 66.  2001. Epidemiology of sepsis: an update. Crit. Care Med. 29:S109–16 [Google Scholar]
  67. Wang H, Yang H, Tracey KJ. 67.  2004. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med. 255:320–31 [Google Scholar]
  68. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M. 68.  et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–51 [Google Scholar]
  69. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. 69.  2000. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165:2950–54 [Google Scholar]
  70. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M. 70.  et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641–50 [Google Scholar]
  71. Yang H, Ochani M, Li J, Qiang X, Tanovic M. 71.  et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101:296–301 [Google Scholar]
  72. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY. 72.  et al. 2007. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care 11:R122 [Google Scholar]
  73. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M. 73.  et al. 2008. Functional roles for C5a receptors in sepsis. Nat. Med. 14:551–57 [Google Scholar]
  74. Plitas G, Burt BM, Nguyen HM, Bamboat ZM, DeMatteo RP. 74.  2008. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J. Exp. Med. 205:1277–83 [Google Scholar]
  75. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y. 75.  et al. 2009. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 32:17–22 [Google Scholar]
  76. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M. 76.  et al. 2009. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc. Res. 81:565–73 [Google Scholar]
  77. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM. 77.  et al. 2006. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25:571–74 [Google Scholar]
  78. Nakamura T, Fujiwara N, Sato E, Kawagoe Y, Ueda Y. 78.  et al. 2009. Effect of polymyxin B-immobilized fiber hemoperfusion on serum high mobility group box-1 protein levels and oxidative stress in patients with acute respiratory distress syndrome. ASAIO J. 55:395–99 [Google Scholar]
  79. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP. 79.  et al. 2005. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135–43 [Google Scholar]
  80. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z. 80.  et al. 2007. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204:2913–23 [Google Scholar]
  81. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R. 81.  et al. 2007. Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R1538–44 [Google Scholar]
  82. Kaczorowski DJ, Nakao A, Vallabhaneni R, Mollen KP, Sugimoto R. 82.  et al. 2009. Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation 87:1455–63 [Google Scholar]
  83. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H. 83.  et al. 2005. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-α and NF-κB. J. Exp. Med. 201:473–84 [Google Scholar]
  84. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK. 84.  et al. 2006. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113:1226–34 [Google Scholar]
  85. Izuishi K, Tsung A, Jeyabalan G, Critchlow ND, Li J. 85.  et al. 2006. Cutting edge: High-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J. Immunol. 176:7154–58 [Google Scholar]
  86. Pisetsky DS, Erlandsson-Harris H, Andersson U. 86.  2008. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res. Ther. 10:209 [Google Scholar]
  87. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K. 87.  et al. 2003. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052–58 [Google Scholar]
  88. Pullerits R, Jonsson IM, Kollias G, Tarkowski A. 88.  2008. Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. Arthritis Res. Ther. 10:R72 [Google Scholar]
  89. Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S. 89.  et al. 2008. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients—a prospective clinical study. Arthritis Res. Ther. 10:R33 [Google Scholar]
  90. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. 90.  1998. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41:1241–50 [Google Scholar]
  91. Sanford AN, Dietzmann K, Sullivan KE. 91.  2005. Apoptotic cells, autoantibodies, and the role of HMGB1 in the subcellular localization of an autoantigen. J. Autoimmun. 25:264–71 [Google Scholar]
  92. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. 92.  2008. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol. Lett. 121:61–73 [Google Scholar]
  93. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T. 93.  et al. 2009. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J. Clin. Immunol. 29:180–89 [Google Scholar]
  94. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J. 94.  et al. 2008. The role of high mobility group box1 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 39:440–47 [Google Scholar]
  95. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T. 95.  et al. 2007. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13:2836–48 [Google Scholar]
  96. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P. 96.  et al. 2003. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 17:1295–97 [Google Scholar]
  97. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ. 97.  et al. 2003. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 63:2188–93 [Google Scholar]
  98. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB. 98.  et al. 2009. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J. Transl. Med. 7:38 [Google Scholar]
  99. Poser I, Golob M, Buettner R, Bosserhoff AK. 99.  2003. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol. Cell. Biol. 23:2991–98 [Google Scholar]
  100. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K. 100.  et al. 2008. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci. 99:1806–12 [Google Scholar]
  101. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K. 101.  et al. 2005. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166:1259–63 [Google Scholar]
  102. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC. 102.  et al. 2000. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354–60 [Google Scholar]
  103. van Beijnum JR, Petersen K, Griffioen AW. 103.  2009. Tumor endothelium is characterized by a matrix remodeling signature. Front. Biosci. 1:216–25 [Google Scholar]
  104. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C. 104.  et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13:1050–59 [Google Scholar]
  105. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C. 105.  et al. 1999. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res. Mol. Brain Res. 71:159–70 [Google Scholar]
  106. Schmidt AM, Yan SD, Yan SF, Stern DM. 106.  2001. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108:949–55 [Google Scholar]
  107. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. 107.  2007. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46:6957–70 [Google Scholar]
  108. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N. 108.  et al. 2007. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 26:3868–78 [Google Scholar]
  109. Wilton R, Yousef MA, Saxena P, Szpunar M, Stevens FJ. 109.  2006. Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expr. Purif. 47:25–35 [Google Scholar]
  110. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M. 110.  et al. 2008. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22:1572–80 [Google Scholar]
  111. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L. 111.  et al. 2008. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22:3716–27 [Google Scholar]
  112. Katsuoka F, Kawakami Y, Arai T, Imuta H, Fujiwara M. 112.  et al. 1997. Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem. Biophys. Res. Commun. 238:512–16 [Google Scholar]
  113. Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M. 113.  1998. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell. Mol. Biol. (Noisy-le-grand) 44:1147–57 [Google Scholar]
  114. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. 114.  1993. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 91:2155–68 [Google Scholar]
  115. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E. 115.  et al. 1993. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143:1699–712 [Google Scholar]
  116. Huttunen HJ, Fages C, Rauvala H. 116.  1999. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274:19919–24 [Google Scholar]
  117. Li J, Qu X, Schmidt AM. 117.  1998. Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J. Biol. Chem. 273:30870–78 [Google Scholar]
  118. Li J, Schmidt AM. 118.  1997. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272:16498–506 [Google Scholar]
  119. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL. 119.  et al. 2003. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 111:959–72 [Google Scholar]
  120. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A. 120.  et al. 1999. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901 [Google Scholar]
  121. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. 121.  2000. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 275:40096–105 [Google Scholar]
  122. Palumbo R, De Marchis F, Pusterla T, Conti A, Alessio M, Bianchi ME. 122.  2009. Src family kinases are necessary for cell migration induced by extracellular HMGB1. J. Leukoc. Biol. 86:617–23 [Google Scholar]
  123. Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M. 123.  et al. 2008. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J. Neurooncol. 87:23–33 [Google Scholar]
  124. Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Munch G. 124.  2003. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J. Neurochem. 87:44–55 [Google Scholar]
  125. Toure F, Zahm JM, Garnotel R, Lambert E, Bonnet N. 125.  et al. 2008. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem. J. 416:255–61 [Google Scholar]
  126. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E. 126.  et al. 2008. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283:34457–68 [Google Scholar]
  127. Kim JY, Park HK, Yoon JS, Kim SJ, Kim ES. 127.  et al. 2008. Advanced glycation end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways. Int. J. Oncol. 33:493–501 [Google Scholar]
  128. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG. 128.  et al. 2006. Key role of src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem. 281:13685–93 [Google Scholar]
  129. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. 129.  2003. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 550:107–13 [Google Scholar]
  130. Allen WE, Zicha D, Ridley AJ, Jones GE. 130.  1998. A role for Cdc42 in macrophage chemotaxis. J. Cell Biol. 141:1147–57 [Google Scholar]
  131. Ridley AJ, Allen WE, Peppelenbosch M, Jones GE. 131.  1999. Rho family proteins and cell migration. Biochem. Soc. Symp. 65:111–23 [Google Scholar]
  132. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS. 132.  2000. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. Mol. Cell 5:13–25 [Google Scholar]
  133. Munch G, Schicktanz D, Behme A, Gerlach M, Riederer P. 133.  et al. 1999. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat. Biotechnol. 17:1006–10 [Google Scholar]
  134. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF. 134.  et al. 2005. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann. N. Y. Acad. Sci. 1043:702–9 [Google Scholar]
  135. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T. 135.  et al. 1998. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J. Am. Soc. Nephrol. 9:2349–56 [Google Scholar]
  136. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. 136.  2006. Diabetes and advanced glycoxidation end products. Diabetes Care 29:1420–32 [Google Scholar]
  137. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B. 137.  et al. 2009. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging. In press [Google Scholar]
  138. Li YM, Tan AX, Vlassara H. 138.  1995. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1:1057–61 [Google Scholar]
  139. Heizmann CW, Fritz G, Schafer BW. 139.  2002. S100 proteins: structure, functions and pathology. Front. Biosci. 7:d1356–68 [Google Scholar]
  140. Donato R. 140.  2001. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33:637–68 [Google Scholar]
  141. Tarabykina S, Kriajevska M, Scott DJ, Hill TJ, Lafitte D. 141.  et al. 2000. Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast two-hybrid system. FEBS Lett. 475:187–91 [Google Scholar]
  142. Kiryushko D, Novitskaya V, Soroka V, Klingelhofer J, Lukanidin E. 142.  et al. 2006. Molecular mechanisms of Ca2+ signaling in neurons induced by the S100A4 protein. Mol. Cell. Biol. 26:3625–38 [Google Scholar]
  143. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W. 143.  et al. 2000. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43:628–37 [Google Scholar]
  144. Foell D, Roth J. 144.  2004. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 50:3762–71 [Google Scholar]
  145. Leclerc E, Fritz G, Vetter SW, Heizmann CW. 145.  2009. Binding of S100 proteins to RAGE: an update. Biochim. Biophys. Acta 1793:993–1007 [Google Scholar]
  146. Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K. 146.  et al. 2008. Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol. 181:1499–506 [Google Scholar]
  147. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. 147.  2003. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 170:3233–42 [Google Scholar]
  148. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C. 148.  et al. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13:1042–49 [Google Scholar]
  149. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D. 149.  et al. 2009. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 7:e97 [Google Scholar]
  150. Pusterla T, de Marchis F, Palumbo R, Bianchi ME. 150.  2009. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 42:308–10 [Google Scholar]
  151. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T. 151.  et al. 2009. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462:726999–103 [Google Scholar]
/content/journals/10.1146/annurev.immunol.021908.132603
Loading
/content/journals/10.1146/annurev.immunol.021908.132603
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error